The Indian Pharmaceutical market (IPM) has registered strong growth of 9.5 per cent to Rs.10,056 crore during January 2018 which highest monthly growth as compared to last four months. According to AIOCD Pharmasofttech AWACS report the IPM growth during the first ten months of 2017-18 restricted to 5.2 per cent mainly due to implementation of GST. The volumes have posted a positive growth however price component is dragging the market. FDC related market showed growth of 18.1 per cent while the non FDC market showed a growth of 9.3 per cent while the single molecules grew at 9.4 per cent during January 2018. MNCs grew by 10.7 per cent as against 9.2 per cent growth achieved by India companies.
From therapy perspective 18 therapies have shown a positive growth. Anti infectives have shown very good double digit during January 2018 of 12.2 per cent, while Dermatology posted double digit growth of 11.9 per cent. Respiratory segment also showed healthy double digit growth of 19.3 per cent. Gastro Intestinal has shown a positive turnaround this month and is growing at 6.4 per cent while Vitamins are also showing at positive growth of 7.2 per cent. Major chronic therapy like Anti-diabetic posted a double digit growth of 10 per cent. Cardio segment has posted better growth for the month of 8.6 per cent, CNS is also moved up by 9.3 per cent compared to last month.
Among the leading 10 companies, Lupin has the highest growth at 16.5 per cent followed by Mankind at 16.4 per cent and Macleods at 14.6 per cent. Among the top 50 companies, 43 corporates have shown positive growth and Allergan has the highest growth of 34.6 per cent followed by Hetero Growing at 31.7 per cent and Win Franco Indian at 20.9 per cent. Other MNCs like MSD achieved growth of 19.6 per cent and Boehringer Ingelheim 16.2 per cent during January 2018. In the Non-NLEM category Indian companies showed a growth of 9.8 per cent whereas MNCs grew at 11.8 per cent.
Abbott HC moved by 13.6 per cent and Abbott India by 18 per cent during January 2018. Sun portfolio has shown double digit growth of 12.9 per cent, while Ranbaxy has also showed double digit growth of 10.4 per cent.
Haryana market grew the highest at 24 per cent followed by Madhya Pradesh growth at 23 per cent & south Rajasthan at 21.5 per cent during January 2018. 29 regions have posted positive growth during January 2018.
Amoxycillin & Clavlulanic acid market clocked a recovery at 14.6 per cent at Rs.171 crore and Glimepiride plus Metformin market achieved growth of 4.7 per cent at Rs.172.4 crore. Azilsartan plain market is now valued at Rs 60.3 crore on MAT basis. Sofosbuvir and its combination market has reached at Rs.591.8 crore. The Luliconazole market touched to Rs.245.3 crore and Tenegliptin and its combinations have crossed Rs.600 crore mark on MAT basis. The market for paracetamol plain improved by 8.5 per cent on monthly basis, however, plain Atorvastatin market remained stagnant at 1.8 per cent growth. Probiotic microbes is showing a double digit growth of 14.2 per cent.
Among the leading brands, Mixtard leads the pack with Rs.45 crore followed by Glycomet GP Rs.35 crore, Spasmoproxyvon plus at Rs.35 crore, Lantus at Rs.33 crore and Glvus Met at Rs.31 crore. Liv 52 registered sales of Rs.25 crore and Janumet touched to Rs.32 crore during January 2018.